Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein encoded by the FOLH1 gene that is physiologically expressed not only on prostate cells but also on a variety of extraprostatic tissues, such as lacrimal and salivary glands, kidneys, liver, and bladder.81 Approximately 86%-100% of ccRCC tumors have been shown to exhibit positive PSMA expression compared to 0%-28% of papillary RCC.82 These findings may support the role of PSMA-based theranostic agents in the management and treatment of ccRCC. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.